CD8A and non-small cell lung carcinoma: Besides, immunotherapy reactivating CD8+ T cells such as anti-PD-1 antibodies exhibits tumor therapeutic promise against NSCLC, and results in 20% tumor remission in the patients’ failed treatments of chemotherapies or targeted therapies [8,9,10].